Radicle Science and Open Book Extracts release the results of the largest ever randomized clinical trial on cannabinoids and pain, and the first study of its kind to examine the impact of rare cannabinoids.
Radicle Science, a leading AI B-corp health technology pioneering large-scale clinical trials on health and wellness products, today announced the results of the largest clinical trial of cannabinoids in history on pain, in partnership with Open Book Extracts (OBX). All formulations in the study of pain on Cannabidiol (CBD) and Rare Cannabinoids were provided by OBX, an NSF-certified manufacturer and distributor of the industry’s most innovative and highest quality cannabinoid ingredients and finished products. .
The OBX Pain Study on CBD and Rare Cannabinoids is the largest randomized, controlled clinical trial of cannabinoids for pain, involving more than 1,600 participants from across the United States and the first of its kind to examine the synergistic impact of rare cannabinoids such as Cannabichromene (CBC). ) and Cannabigerol (CBG) on pain.
The results demonstrate clinically significant improvements in pain in the various formulations of CBD and rare cannabinoids studied.
CLINICAL TRIAL METHODOLOGY
The OBX Pain Study on CBD and Rare Cannabinoids was a blinded, randomized, controlled clinical trial to evaluate the effects of various cannabinoid formulations on pain, as well as other health outcomes. The test was designed to examine whether adding other ingredients to a formulation (“reinforced products”) in conjunction with CBD could lead to better results than with CBD alone. The trial included 6 arms of product, all of which contained CBD at 40 mg per serving. Most weapons also contain various levels of rare cannabinoids, including CBG and CBC.
A diverse sample of 1629 pain patients from across the United States were randomized to receive and take one of these product formulations for one month while reporting their pain relative to specific benchmarks including severity, general activity, sleep quality, symptoms of anxiety and general quality of life.
SIGNIFICANT RESEARCH RESULTS
All of the enhanced product formulations included in this clinical trial have led to statistically significant improvements in pain, anxiety, sleep quality, and overall quality of life.
On average, almost half (44.8%) of the participants who received any of the boosted products experienced a clinically significant improvement in their pain, meaning that they achieved a marked and palpable improvement in their quality of life for amidst the symptoms of pain.
Overall, the various enhanced formulations have done almost the same for improving pain, anxiety, sleep quality, and quality of life. However, for people with moderate pain, there was evidence that adding 20mg CBC to a formulation containing 40mg of CBD could significantly improve its analgesic effects, especially when this fortified product was taken for 2 or more weeks.
All products tested were considered safe for consumption. Only about 1 in 10 participants reported side effects, and none were severe.
KEY TAKEAWAY: CLINICALLY SIGNIFICANT IMPROVEMENTS
All formulations in this trial led to statistically significant and clinically significant improvement in pain after only 4 weeks – all with minimal side effects.
“We at OBX are fundamentally dedicated to supporting all consumers in their effort to feel their best from the inside out through a holistic universe of effective cannabinoid products, based on evidence of the highest quality,” said OBX CEO Dave Neundorfer. “While existing studies suggest that cannabidiol and rare cannabinoids, including CBG and CBC, have considerable potential to sustain well-being, there has been an obvious gap in scientifically valid research dedicated to guiding effective product development. we have collaborated with renowned medical experts and data scientists at Radicle Science to better understand the potential of rare cannabinoids as an ingredient and, in particular, their ability to sustain a better quality of life in relation to pain.
“It’s a privilege to make history with OBX,” said Dr. Jeff Chen, MD, CEO of Radicle Science and founder and former executive director of the UCLA Cannabis Research Initiative. “Rare cannabinoids are present in a variety of health and wellness products that contain cannabis and cannabis, but there has been virtually no clinical data on their effectiveness for any medical condition, including pain. Radicle Science has evaluated for first time in history the potential synergistic effects of certain rare cannabinoids on pain and demonstrated that these natural products can have a measurable positive impact.
The OBX Pain Study on CBD and Rare Cannabinoids is the first complete clinical trial of OBX with Radicle Science. Radicle Science and OBX continue their collaboration with similar large-scale, blinded, randomized, controlled trials on rare cannabinoids, including THCV, CBN, CBG, and CBC, that OBX provides. Radicle will study its effects on other health and lifestyle benchmarks, such as energy, focus, appetite, sleep disorders, stress, and anxiety, through thousands of study participants.
Pelin Thorogood, co-founder and CEO of Radicle Science, added: “We look forward to seeing if adding a rare cannabinoid could increase the effects of CBD. We will further explore the effect of the entourage with an upcoming study.” “Radicle Spectrum, which will be the first lead-in study comparing full-spectrum or broad-spectrum CBD to isolate and placebo. We hope this study provides data to help the FDA determine whether CBD isolate is a drug.” .
About Radicle Science
Radicle Science is an AI-led B-body of health that offers the first scalable pathway to validate and predict the effects of health and wellness products, transforming them into precision solutions that democratize disease or enhance human function. Radicle Science leverages a proprietary data analytics platform and a virtual, consumer-oriented (D2C) clinical trial model to provide objective data on health outcomes across diverse populations and conditions, all at a fraction of the cost and time. traditional methods. The company’s Radicle Vision is a future where affordable and affordable health and wellness products are trusted by patients, advised by healthcare providers, reimbursed by insurance and used as pharmaceutical drugs. To learn more about Radicle Science, visit www.RadicleScience.com.
About open book extracts
Headquartered in Roxboro, NC, Open Book Extracts is a cGMP certified manufacturer of premium plant-based cannabinoid products, which aims to be the true north of the industry by offering premium products, exceptional service and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near the North Carolina Research Triangle, proprietary refining and conversion methods supported by a growing IP portfolio and a team of PhD chemists and executives of experienced companies, OBX is the trust. partners for global brands looking to enter the market. Learn more at www.OpenBookExtracts.com.